SCL Science

SCL Science EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of SCL Science (246960.KQ) as of Oct 17, 2026 is -25.28. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -20.56 — a change of 22.93% (lower).

EV/EBIT

-25.28

YoY

22.93%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of SCL Science is 2025 -25.28 . EV/EBIT (Enterprise Value to EBIT) of SCL Science was 2024 -20.56 . It decreases by 22.93% lower compared to the previous year.

The SCL Science EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2018
-28.61 KRW
Jan 1, 2019
-18.97 KRW
Jan 1, 2020
-25.30 KRW
Jan 1, 2021
-16.27 KRW
Jan 1, 2022
-14.01 KRW
Jan 1, 2023
-10.59 KRW
Jan 1, 2024
-20.56 KRW
Jan 1, 2025
-25.28 KRW
The SCL Science EV/EBIT history
YEAREV/EBITYoY
-25.28+22.93%
-20.56+94.21%
-10.59-24.43%
-14.01-13.86%
-16.27-35.71%
-25.30+33.40%
-18.97-33.70%
-28.61+15.75%
-24.71-41.20%
-42.03-21.87%
-53.79—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

SCL Science Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides SCL Science's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates SCL Science's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots SCL Science's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if SCL Science grows earnings faster than its peers.

SCL Science Stock analysis

What does SCL Science do? SCL Science Inc, listed on the Korean stock exchange with ticker 246960.KQ and ISIN KR7246960009, is a healthcare company headquartered in Seoul, South Korea. The company went public on February 1, 2019, as indicated by its IPO date. SCL Science Inc operates within the healthcare sector, focusing on the development and commercialization of medical products. According to the provided information, the company manufactures and sells hemostatic medical agents, which are used to control bleeding in medical procedures. The company's products include medical hemostats and sealants that utilize biomimetic technology, a technology inspired by natural biological processes. The company's website is innotherapy.com, which may provide further details about its products and services. SCL Science Inc is based in Seoul, South Korea, and its primary business activities are centered around the healthcare industry, specifically in the field of hemostatic solutions. The company's focus on biomimetic technology suggests an innovative approach to developing medical products that mimic natural biological mechanisms. The company's operations are likely aimed at providing medical professionals with effective tools for managing bleeding during surgical and other medical procedures. The company's market presence is within South Korea, though it may have international reach through its website and product distribution channels. The information provided does not include details on the company's revenue, market share, or specific competitors, nor does it mention any acquisitions or key personnel beyond the general description of its business activities. SCL Science is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SCL Science stock

EV/EBIT (Enterprise Value to EBIT) of SCL Science is -25.28 in 2025.

EV/EBIT (Enterprise Value to EBIT) of SCL Science changed from -20.56 to -25.28, representing a 22.93% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) SCL Science since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s SCL Science with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — SCL Science

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — SCL Science